Medical - Healthcare Information Services
Compare Stocks
4 / 10Stock Comparison
PRVA vs OSCR vs CNC vs ALHC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
PRVA vs OSCR vs CNC vs ALHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $3.01B | $5.41B | $27.13B | $3.73B |
| Revenue (TTM) | $2.25B | $13.30B | $198.10B | $4.26B |
| Net Income (TTM) | $3.08B | $-39M | $-6.44B | $20M |
| Gross Margin | 7.0% | 17.4% | 14.9% | 9.0% |
| Operating Margin | 1.6% | 0.1% | -3.7% | 0.8% |
| Forward P/E | 68.5x | 34.7x | 16.3x | 140.9x |
| Total Debt | $10M | $430M | $18.78B | $338M |
| Cash & Equiv. | $480M | $2.77B | $17.89B | $578M |
PRVA vs OSCR vs CNC vs ALHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Privia Health Group… (PRVA) | 100 | 66.1 | -33.9% |
| Oscar Health, Inc. (OSCR) | 100 | 91.8 | -8.2% |
| Centene Corporation (CNC) | 100 | 89.0 | -11.0% |
| Alignment Healthcar… (ALHC) | 100 | 68.8 | -31.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRVA vs OSCR vs CNC vs ALHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PRVA is the clearest fit if your priority is quality.
- 137.2% margin vs CNC's -3.3%
OSCR is the clearest fit if your priority is momentum.
- +22.6% vs CNC's -12.7%
CNC has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.39
- 81.2% 10Y total return vs ALHC's 5.4%
- Lower volatility, beta 0.39, Low D/E 93.6%, current ratio 1.68x
- Beta 0.39, current ratio 1.68x
ALHC is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 46.1% revenue growth vs CNC's 19.4%
- 1.8% ROA vs CNC's -7.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 46.1% revenue growth vs CNC's 19.4% | |
| Value | Lower P/E (16.3x vs 140.9x) | |
| Quality / Margins | 137.2% margin vs CNC's -3.3% | |
| Stability / Safety | Beta 0.39 vs OSCR's 1.84 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +22.6% vs CNC's -12.7% | |
| Efficiency (ROA) | 1.8% ROA vs CNC's -7.9% |
PRVA vs OSCR vs CNC vs ALHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PRVA vs OSCR vs CNC vs ALHC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
OSCR leads in 2 of 6 categories
CNC leads 1 • PRVA leads 0 • ALHC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
OSCR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CNC is the larger business by revenue, generating $198.1B annually — 88.2x PRVA's $2.2B. PRVA is the more profitable business, keeping 137.2% of every revenue dollar as net income compared to CNC's -3.3%. On growth, OSCR holds the edge at +52.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2.2B | $13.3B | $198.1B | $4.3B |
| EBITDAEarnings before interest/tax | $48M | $40M | -$5.9B | $66M |
| Net IncomeAfter-tax profit | $3.1B | -$39M | -$6.4B | $20M |
| Free Cash FlowCash after capex | -$49.3B | $2.8B | $6.3B | $237M |
| Gross MarginGross profit ÷ Revenue | +7.0% | +17.4% | +14.9% | +9.0% |
| Operating MarginEBIT ÷ Revenue | +1.6% | +0.1% | -3.7% | +0.8% |
| Net MarginNet income ÷ Revenue | +137.2% | -0.3% | -3.3% | +0.5% |
| FCF MarginFCF ÷ Revenue | -21.9% | +21.0% | +3.2% | +5.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.8% | +52.6% | +7.1% | +33.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -33.3% | +125.0% | +18.3% | +2.1% |
Valuation Metrics
CNC leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRVA's 57.6x EV/EBITDA is more attractive than ALHC's 77.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3.0B | $5.4B | $27.1B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $3.1B | $28.0B | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | 133.28x | -12.35x | -4.03x | -4932.43x |
| Forward P/EPrice ÷ next-FY EPS est. | 68.48x | 34.65x | 16.29x | 140.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 57.62x | — | — | 77.12x |
| Price / SalesMarket cap ÷ Revenue | 1.42x | 0.46x | 0.14x | 0.94x |
| Price / BookPrice ÷ Book value/share | 3.91x | 5.58x | 1.35x | 20.16x |
| Price / FCFMarket cap ÷ FCF | 18.58x | 5.11x | 6.28x | 32.95x |
Profitability & Efficiency
Evenly matched — PRVA and ALHC each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
ALHC delivers a 11.5% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-29 for CNC. PRVA carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), CNC scores 6/9 vs OSCR's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +1.5% | -3.3% | -28.6% | +11.5% |
| ROA (TTM)Return on assets | +0.9% | -0.6% | -7.9% | +1.8% |
| ROICReturn on invested capital | +9.9% | — | -21.6% | — |
| ROCEReturn on capital employed | +4.6% | -25.3% | -14.6% | +2.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.01x | 0.44x | 0.94x | 1.89x |
| Net DebtTotal debt minus cash | -$470M | -$2.3B | $889M | -$240M |
| Cash & Equiv.Liquid assets | $480M | $2.8B | $17.9B | $578M |
| Total DebtShort + long-term debt | $10M | $430M | $18.8B | $338M |
| Interest CoverageEBIT ÷ Interest expense | — | -0.57x | -9.03x | 1.27x |
Total Returns (Dividends Reinvested)
OSCR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OSCR five years ago would be worth $9,271 today (with dividends reinvested), compared to $7,388 for PRVA. Over the past 12 months, OSCR leads with a +22.6% total return vs CNC's -12.7%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs PRVA's -7.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.3% | +39.4% | +31.5% | -9.7% |
| 1-Year ReturnPast 12 months | +2.9% | +22.6% | -12.7% | +17.6% |
| 3-Year ReturnCumulative with dividends | -19.8% | +177.5% | -19.5% | +152.4% |
| 5-Year ReturnCumulative with dividends | -26.1% | -7.3% | -22.0% | -22.7% |
| 10-Year ReturnCumulative with dividends | +4.3% | -40.0% | +81.2% | +5.4% |
| CAGR (3Y)Annualised 3-year return | -7.1% | +40.5% | -7.0% | +36.2% |
Risk & Volatility
Evenly matched — PRVA and CNC each lead in 1 of 2 comparable metrics.
Risk & Volatility
CNC is the less volatile stock with a 0.39 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRVA currently trades 90.5% from its 52-week high vs ALHC's 76.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.03x | 1.84x | 0.39x | 0.75x |
| 52-Week HighHighest price in past year | $26.51 | $23.80 | $64.15 | $23.87 |
| 52-Week LowLowest price in past year | $18.77 | $10.69 | $25.08 | $11.63 |
| % of 52W HighCurrent price vs 52-week peak | +90.5% | +87.7% | +85.7% | +76.5% |
| RSI (14)Momentum oscillator 0–100 | 55.6 | 78.5 | 83.5 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 901K | 6.5M | 5.8M | 3.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PRVA as "Buy", OSCR as "Hold", CNC as "Buy", ALHC as "Buy". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs -19.7% for OSCR (target: $17).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $31.67 | $16.75 | $51.00 | $24.83 |
| # AnalystsCovering analysts | 22 | 11 | 43 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.8% | 0.0% |
OSCR leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CNC leads in 1 (Valuation Metrics). 2 tied.
PRVA vs OSCR vs CNC vs ALHC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PRVA or OSCR or CNC or ALHC a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus 19. 4% for Centene Corporation (CNC). Privia Health Group, Inc. (PRVA) offers the better valuation at 133. 3x trailing P/E (68. 5x forward), making it the more compelling value choice. Analysts rate Privia Health Group, Inc. (PRVA) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRVA or OSCR or CNC or ALHC?
On forward P/E, Centene Corporation is actually cheaper at 16.
3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PRVA or OSCR or CNC or ALHC?
Over the past 5 years, Oscar Health, Inc.
(OSCR) delivered a total return of -7. 3%, compared to -26. 1% for Privia Health Group, Inc. (PRVA). Over 10 years, the gap is even starker: CNC returned +81. 2% versus OSCR's -40. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRVA or OSCR or CNC or ALHC?
By beta (market sensitivity over 5 years), Centene Corporation (CNC) is the lower-risk stock at 0.
39β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 369% more volatile than CNC relative to the S&P 500. On balance sheet safety, Privia Health Group, Inc. (PRVA) carries a lower debt/equity ratio of 1% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PRVA or OSCR or CNC or ALHC?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus 19. 4% for Centene Corporation (CNC). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRVA or OSCR or CNC or ALHC?
Privia Health Group, Inc.
(PRVA) is the more profitable company, earning 1. 1% net margin versus -3. 8% for Oscar Health, Inc. — meaning it keeps 1. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRVA leads at 1. 6% versus -3. 9% for CNC. At the gross margin level — before operating expenses — OSCR leads at 14. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRVA or OSCR or CNC or ALHC more undervalued right now?
On forward earnings alone, Centene Corporation (CNC) trades at 16.
3x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 124. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.
08Which pays a better dividend — PRVA or OSCR or CNC or ALHC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is PRVA or OSCR or CNC or ALHC better for a retirement portfolio?
For long-horizon retirement investors, Centene Corporation (CNC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
39)). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNC: +81. 2%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRVA and OSCR and CNC and ALHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.